Effect of GLP-1 and GIP on Insulin Secretion in Type-1 Diabetes Mellitus

Effect of GLP-1 and GIP on the Maximal Insulin Secretory Capacity in Type-1 Diabetes Mellitus

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00603031

Enrollment

Registered

2008-01-28

Start date

2008-01-31

Completion date

2008-06-30

Last updated

2011-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type-1 Diabetes Mellitus

Brief summary

study hypothesis: treatment with GLP-1 and/or GIP is able to potentiate the maximal stimulated insulin secretion even in c-peptide negative type-1 diabetic patients classified as having no residual beta cell function left.

Interventions

OTHERglucagon like peptide -1

continuous infusion 1,2 pmol pr. kg pr minute at 120 minutes

OTHERNaCl

infusion with NaCl for 120 minutes as placebo-arm

OTHERglucose dependent insulinotropic polypeptide

continuous infusion with GIP-1 (3,6pmol/kg/min) at 120 minutes.

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* Age 18-60 years * Type-1 diabetes diagnosed between 5-40 years of age * Normal weight(BMI 18-27), * Insulin treatment from time of diagnosis.

Exclusion criteria

* Severe complications to diabetes * Abnormal liver or kidney function * Haemoglobin below the lower limit * Macroalbuminuria * Systemic disease * Pregnancy.

Design outcomes

Primary

Measure	Time frame
phase insulin response and phase insulin response measured as incremental area under the curve from 0-10 minutes and incremental area under the curve from 10-45 minutes respectively after iv glucose	2 hours

Secondary

Measure	Time frame
maximal insulin response defined as mean insulin at time 47 and 49 minutes (2 and 4 minutes after infusion of L-Arginine)	2 hours

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026